Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TNDM

TNDM - Tandem Diabetes Care Inc Stock Price, Fair Value and News

$19.10-1.05 (-5.21%)
Market Closed

43/100

TNDM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

43/100

TNDM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$18.07

Target 3M

$19.42

Target 6M

$18.96

TNDM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TNDM Price Action

Last 7 days

-7.9%

Last 30 days

-14.5%

Last 90 days

30.9%

Trailing 12 Months

-47.5%

TNDM RSI Chart

TNDM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TNDM Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-6.37

Price/Sales (Trailing)

1.29

EV/EBITDA

-7.99

Price/Free Cashflow

-51.54

TNDM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$18.07

Target 3M

$19.42

Target 6M

$18.96

TNDM Fundamentals

TNDM Revenue

Revenue (TTM)

1.0B

Rev. Growth (Yr)

2.17%

Rev. Growth (Qtr)

3.56%

TNDM Earnings

Earnings (TTM)

-203.4M

Earnings Growth (Yr)

8.97%

Earnings Growth (Qtr)

59.61%

TNDM Profitability

EBT Margin

-20.35%

Return on Equity

-152.95%

Return on Assets

-23.25%

Free Cashflow Yield

-1.94%

TNDM Investor Care

Shares Dilution (1Y)

3.24%

Diluted EPS (TTM)

-3.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025983.0M1.0B1.0B0
2024770.0M796.0M854.4M940.2M
2023794.7M790.3M771.4M747.7M
2022737.7M765.8M790.7M801.2M
2021541.9M604.8M660.9M702.8M
2020394.2M410.2M439.2M498.8M
2019222.6M281.7M330.1M362.3M
2018115.9M128.7M148.0M183.9M
201783.2M81.5M96.2M107.6M
201680.6M87.9M84.5M84.2M
201554.0M59.4M61.6M72.8M
201431.6M36.3M42.1M49.7M
20139.1M15.7M22.4M29.0M
20120002.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Tandem Diabetes Care Inc

TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
 CEO
 WEBSITEtandemdiabetes.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES2600

Tandem Diabetes Care Inc Frequently Asked Questions

TNDM is the stock ticker symbol of Tandem Diabetes Care Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Tandem Diabetes Care Inc is 1.3 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TNDM's fair value in chart for subscribers.

The fair value guage provides a quick view whether TNDM is over valued or under valued. Whether Tandem Diabetes Care Inc is cheap or expensive depends on the assumptions which impact Tandem Diabetes Care Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNDM.

As of Wed Jan 28 2026, TNDM's PE ratio (Price to Earnings) is -6.37 and Price to Sales (PS) ratio is 1.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNDM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Tandem Diabetes Care Inc has provided -0.144 (multiply by 100 for percentage) rate of return.